Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Tauber

Ophthalmology

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Ophthalmology|August 17, 2005
Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 yearsLaurie D Barber, Stephen C Pflugfelder, Joseph Tauber, et al.
Ophthalmology|December 27, 2022
NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI StudyJoseph Tauber, Gregg J Berdy, David L Wirta, et al.
Ophthalmology|October 4, 2011
Clinical characteristics of a large cohort of patients with scleritis and episcleritisMaite Sainz de la Maza, Nicolas Molina, Luis Alonso Gonzalez-Gonzalez, et al.
Ophthalmology|September 15, 2015
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 StudyJoseph Tauber, Paul Karpecki, Robert Latkany, et al.
Ophthalmology|October 22, 2011
Scleritis therapyMaite Sainz de la Maza, Nicolas Molina, Luis Alonso Gonzalez-Gonzalez, et al.
Ophthalmology|April 3, 2012
Clinical features and presentation of infectious scleritis from herpes viruses: a report of 35 casesLuis Alonso Gonzalez-Gonzalez, Nicolas Molina-Prat, Priyanka Doctor, et al.
Ophthalmology|January 13, 2017
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)Edward J Holland, Jodi Luchs, Paul M Karpecki, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Ophthalmology|August 17, 2005
Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 yearsLaurie D Barber, Stephen C Pflugfelder, Joseph Tauber, et al.
Ophthalmology|December 27, 2022
NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI StudyJoseph Tauber, Gregg J Berdy, David L Wirta, et al.
Ophthalmology|October 4, 2011
Clinical characteristics of a large cohort of patients with scleritis and episcleritisMaite Sainz de la Maza, Nicolas Molina, Luis Alonso Gonzalez-Gonzalez, et al.
Ophthalmology|September 15, 2015
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 StudyJoseph Tauber, Paul Karpecki, Robert Latkany, et al.
Ophthalmology|October 22, 2011
Scleritis therapyMaite Sainz de la Maza, Nicolas Molina, Luis Alonso Gonzalez-Gonzalez, et al.
Ophthalmology|April 3, 2012
Clinical features and presentation of infectious scleritis from herpes viruses: a report of 35 casesLuis Alonso Gonzalez-Gonzalez, Nicolas Molina-Prat, Priyanka Doctor, et al.
Ophthalmology|January 13, 2017
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)Edward J Holland, Jodi Luchs, Paul M Karpecki, et al.
Pageof 1